Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{184140,
        author = {Dr. Prekshaben Kiranbhai Patel and Dr.S.R.Ram and Dr.Milansinh Gohil and Mrs. Hetu Patel},
        title = {Emerging Approaches to Opioid-Free Pain Relief: A Review of Suzetrigine’s FDA Approval},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {4},
        pages = {1328-1336},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=184140},
        abstract = {Opioids are among the most potent analgesics and are commonly prescribed to manage persistent or severe pain. They are often used by individuals with chronic conditions such as headaches and backaches, as well as by patients recovering from surgery or experiencing pain related to cancer, sports injuries, accidents, or other trauma. While effective, opioids carry a high risk of side effects and addiction. In contrast, non-opioid analgesics are typically the first-line treatment for mild to moderate pain due to their safer profile. Recently, on January 30, 2025, the U.S. Food and Drug Administration (FDA) approved a novel non-opioid analgesic, Suzetrigine, marketed under the brand name Journavx™, for the treatment of moderate to severe acute pain. This approval marks a significant advancement in pain management, offering a safer alternative to opioids with a lower risk of addiction and fewer side effects.},
        keywords = {opioids, non-opioids, FDA, acute sever pain, drug, chronic pain, treatment, Suzetrigine},
        month = {September},
        }